{"id":"NCT01806259","sponsor":"Universit√© Catholique de Louvain","briefTitle":"Ketorolac in Breast Cancer Surgery","officialTitle":"Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2015-10","completion":"2018-09","firstPosted":"2013-03-07","resultsPosted":"2020-01-18","lastUpdate":"2020-04-07"},"enrollment":203,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Curative Breast Cancer Surgery","Inflammatory Positive/Negative Status","Pre Surgical Incision Administration"],"interventions":[{"type":"DRUG","name":"Ketorolac 30 mg IV","otherNames":["ketorolac tromethamine"]},{"type":"DRUG","name":"Placebos","otherNames":["NaCl 0.9%"]}],"arms":[{"label":"ketorolac 30 mg","type":"EXPERIMENTAL"},{"label":"NaCl 0.9% 3mL","type":"PLACEBO_COMPARATOR"}],"summary":"Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.","primaryOutcome":{"measure":"Recurrence-free Survival","timeFrame":"5 years","effectByArm":[{"arm":"Ketorolac 30 mg","deltaMin":80,"sd":null},{"arm":"NaCl 0.9% 3mL","deltaMin":96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Belgium"]},"refs":{"pmids":["20435950","31800611","23937996"],"seeAlso":["http://www.anesthesia-analgesia.org"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":96},"commonTop":[]}}